TY - JOUR T1 - Late-breaking abstract: Profiling of single maintenance and reliever therapy (SMART) dosing instructions of budesonide/formoterol (BFC) in clinical practice JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P1450 AU - Rachael DiSantostefano AU - Nada Boudiaf AU - David Stempel AU - Neil Barnes Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P1450.abstract N2 - Rationale: To describe clinical trends in dosing instructions for SMART for BFC in asthma.Methods: This study examined dosing instructions for BFC in asthma based on the CPRD-GOLD data (2009-2013), a primary care database in the United Kingdom. Patient prescriptions of BFC and short-acting beta-agonists (SABA) were described for one year from the index BFC prescription. SMART dosing was determined when prescription instructions indicated twice daily dosing with ¡°and when required¡±.Results: There were 119,802 BFC prescriptions in 14,818 patients, where <1% of prescriptions (n=1,154 ) included SMART dosing instructions during the period 2009-2013. At the index BFC prescription, 1.2% of patients (173 of 14,818) had with evidence SMART dosing, but half (53%, n=91) of these patients were prescribed ¡Ý1 short-acting beta-agonists (SABA) in the year following the index prescription versus 82% those without SMART dosing. Among patients with SABA prescriptions, the mean number of SABA canisters prescribed was similar (5.7 and 5.5) for SMART (n=91) and other dosing groups (n=11,968), respectively. The mean number of BFC canisters was also similar for SMART and other dosing groups during the period (4.6 and 4.8).Conclusions: These results demonstrate that SMART dosing for BFC were rarely prescribed according to electronic medical records in patients with asthma (1.2% or 173 of 14,818) in UK clinical practice, as noted in earlier work (Boyter, Respir Med. 2011 Jun;105(6):864-8). Of those with SMART instructions, most patients still were prescribed rescue inhalers and similar amounts of BFC than those patients without SMART dosing.(GSK-funded, PJ2269) ER -